Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy
Journal of Psychoactive Drugs March 15, 2019 Jennifer Dore, Brent Turnipseed, Shannon Dwyer et al. 207 citations
Ketamine, the only legal psychedelic medicine for mental health, is typically given intravenously for treatment-resistant depression without psychotherapy, viewing its psychedelic effects as side effects. The authors argue it can benefit a wider range of patients when combined with psychotherapy, using its psychedelic properties without IV access, and its safety supports office or supervised at-home use. They describe Ketamine Assisted Psychotherapy (KAP) as a tailored method and present demographic and outcome data from 235 patients. Findings suggest KAP effectively decreases depression and anxiety in private practice, especially for older patients and those with severe symptoms.